IPC-Stelle: A61K 39/095 [Version 7 (gültig ab 01.2000)]

Symbol	Typ	Titel
A	SK	HUMAN NECESSITIES
A61	USK	HEALTH; AMUSEMENT
A61	KL	MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K	UKL	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01 , C07 , C08 , C12N; soap compositions C11D; micro-organisms per se C12N)
A61K 6/00	HGR	Preparations for dentistry (teeth cleaning preparations A61K 7/16; dentistry A61C; fastening dental prostheses in the mouth using adhesive foils or adhesive compositions A61C 13/23) [3]
A61K 6/02	UGR1	. Use of preparations for artificial teeth, for filling or for capping teeth [3]
A61K 6/027	UGR2	. . Use of non-metallic elements or compounds thereof, e.g. carbon [5]
A61K 6/033	UGR3	. . . Phosphorus compounds, e.g. apatite [5]
A61K 6/04	UGR2	. . Use of metals or alloys (alloys per se C22C) [3]
A61K 6/05	UGR3	. . . Amalgams [5]
A61K 6/06	UGR2	. . Use of inorganic cements (cements per se C04B) [3]
A61K 6/08	UGR2	. . Use of natural or synthetic resins (resins per se C08) [3]
A61K 6/083	UGR3	. . . Compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds [5]
A61K 6/087	UGR3	. . . Compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds [5]
A61K 6/09	UGR4	. . . . Polyurethanes [5]
A61K 6/093	UGR4	. . . . Polyorganosilicon compounds [5]
A61K 6/097	UGR3	. . . Polysaccharides [5]
A61K 6/10	UGR1	. Compositions for taking dental impressions (impression methods A61C 9/00) [3]
A61K 7/00	HGR	Cosmetics or similar toilet preparations (casings or accessories for storing or handling of solid or pasty toilet or cosmetic substances A45D 40/00)
A61K 7/02	UGR1	. Make-up materials; Preparations for removing them; Body powders [2]
A61K 7/021	UGR2	. . Preparations containing skin colorant (face powders A61K 7/035; tanning preparations A61K 7/42) [2]
A61K 7/025	UGR3	. . . for lips [2]
A61K 7/027	UGR4	. . . . Lipsticks [2]
A61K 7/031	UGR3	. . . for cheeks, e.g. rouge [2]
A61K 7/032	UGR3	. . . for eyes [2]
A61K 7/035	UGR2	. . Face or body powders for grooming, adorning or absorbing [2]
A61K 7/04	UGR1	. Manicure or pedicure compositions
A61K 7/043	UGR2	. . Nail coatings [2]
A61K 7/047	UGR2	. . Nail coating removers [2]
A61K 7/06	UGR1	. Preparations, e.g. lotions or powders, for care of the hair; Preparations to promote hair growth or to aid in hair removal, e.g. shaving preparations [2]
A61K 7/07	UGR2	. . Hair powders [2]
A61K 7/075	UGR2	. . Preparations specially adapted for washing the hair, e.g. containing hair conditioning substances [4]
A61K 7/08	UGR2	. . Preparations for rinsing the hair
A61K 7/09	UGR2	. . Preparations for waving or straightening the hair [2]
A61K 7/11	UGR2	. . Preparations for fixing the hair [2]
A61K 7/13	UGR2	. . Preparations for dyeing the hair [2]
A61K 7/135	UGR2	. . Preparations for bleaching the hair [2]
A61K 7/15	UGR2	. . Shaving preparations (soaps or detergent compositions, e.g. shaving soaps, C11D) [2]
A61K 7/155	UGR2	. . Depilatories [2]
A61K 7/16	UGR1	. Preparations for cleaning the teeth or mouth, e.g. tooth-pastes; Mouthwashes
A61K 7/18	UGR2	. . Preparations containing fluorine compounds [2]
A61K 7/20	UGR2	. . Preparations containing compounds releasing oxygen or chlorine [2]
A61K 7/22	UGR2	. . Preparations containing ammonia, amines or derivatives thereof, e.g. urea [2]
A61K 7/24	UGR2	. . Preparations containing hydroxy-carboxylic acids or derivatives thereof, i.e. compounds wherein the oxygen of the hydroxy group and the carbonyl of the carboxylic acid group are retained [2]
A61K 7/26	UGR2	. . Preparations containing plant or animal extracts, e.g. chlorophyll (A61K 7/28 takes precedence) [2]
A61K 7/28	UGR2	. . Preparations containing enzymes [2]
A61K 7/30	UGR2	. . Preparations for cleaning dentures [2]
A61K 7/32	UGR1	. Anti-perspirants or body deodorants (deodorants for non-body applications A61L 9/01) [2]
A61K 7/34	UGR2	. . Preparations containing zirconium compounds [2]
A61K 7/36	UGR2	. . Preparations containing zinc compounds [2]
A61K 7/38	UGR2	. . Preparations containing aluminium compounds [2]
A61K 7/40	UGR1	. Barrier compositions; Chemical agents brought into direct contact with the skin of living human or animal bodies for affording protection against external influences, e.g. sunlight, X- or other active rays, corrosive materials, bacteria, insect stings (chemical means for combating harmful chemical agents A62D 3/00) [2]
A61K 7/42	UGR2	. . Topical sun or radiation screening or tanning preparations [2]
A61K 7/44	UGR3	. . . Preparations containing aromatic acids or derivatives thereof, e.g. aminobenzoic acid, methyl salicylate [2]
A61K 7/46	UGR1	. Perfume compositions (essential oils, recovery thereof C11B 9/00) [2]
A61K 7/48	UGR1	. Preparations for the care of the skin (A61K 7/02 , A61K 7/40 take precedence) [2]
A61K 7/50	UGR2	. . Washing or bathing preparations (soaps or detergent compositions C11D) [2]
A61K 9/00	HGR	Medicinal preparations characterised by special physical form (nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K 49/18; preparations containing radioactive substances A61K 51/12)
A61K 9/02	UGR1	. Suppositories; Bougies; Bases for suppositories or bougies (apparatus for making A61J 3/08; devices for introducing into the body A61M 31/00)
A61K 9/06	UGR1	. Ointments; Bases therefor (apparatus for making A61J 3/04)
A61K 9/08	UGR1	. Solutions [2, 3]
A61K 9/10	UGR1	. Dispersions; Emulsions [2, 3]
A61K 9/107	UGR2	. . Emulsions [5]
A61K 9/113	UGR3	. . . Multiple emulsions, e.g. oil-in-water-in-oil [5]
A61K 9/12	UGR2	. . Aerosols; Foams [2, 3]
A61K 9/127	UGR2	. . Liposomes [5]
A61K 9/133	UGR3	. . . Unilamellar vesicles [5]
A61K 9/14	UGR1	. Particulate form, e.g. powders (microcapsules A61K 9/50) [2]
A61K 9/16	UGR2	. . Agglomerates; Granulates; Microbeadlets [2]
A61K 9/18	UGR2	. . Adsorbates [2]
A61K 9/19	UGR2	. . lyophilised [6]
A61K 9/20	UGR1	. Pills, lozenges or tablets [2]
A61K 9/22	UGR2	. . Sustained or differential release type [2]
A61K 9/24	UGR3	. . . Layered or laminated unitary dosage forms [2]
A61K 9/26	UGR3	. . . Discrete particles in supporting matrix [2]
A61K 9/28	UGR2	. . Dragees; Coated pills or tablets [2]
A61K 9/30	UGR3	. . . Organic coatings [2]
A61K 9/32	UGR4	. . . . containing solid synthetic polymers [2]
A61K 9/34	UGR4	. . . . containing natural gums or resins [2]
A61K 9/36	UGR4	. . . . containing carbohydrates or derivatives thereof (A61K 9/34 takes precedence) [2]
A61K 9/38	UGR4	. . . . containing proteins or derivatives thereof [2]
A61K 9/40	UGR5	. . . . . Gelatin containing [2]
A61K 9/42	UGR4	. . . . containing waxes, higher fatty acids, higher fatty alcohols, or derivatives thereof, e.g. chocolate [2]
A61K 9/44	UGR2	. . printed, embossed, grooved, or perforated [2]
A61K 9/46	UGR2	. . effervescent [2]
A61K 9/48	UGR1	. Preparations in capsules, e.g. of gelatin, of chocolate [2]
A61K 9/50	UGR2	. . Microcapsules (A61K 9/52 takes precedence) [2]
A61K 9/51	UGR3	. . . Nanocapsules [5]
A61K 9/52	UGR2	. . Sustained or differential release type [2]
A61K 9/54	UGR3	. . . containing discrete particles with coatings of different thicknesses or different materials [2]
A61K 9/56	UGR4	. . . . Organic coatings [2]
A61K 9/58	UGR5	. . . . . containing solid synthetic polymers [2]
A61K 9/60	UGR5	. . . . . containing natural gums or resins [2]
A61K 9/62	UGR5	. . . . . containing carbohydrates or derivatives thereof (A61K 9/60 takes precedence) [2]
A61K 9/64	UGR5	. . . . . containing proteins or derivatives thereof [2]
A61K 9/66	UGR3	. . . containing emulsions, dispersions or solutions [2]
A61K 9/68	UGR1	. chewing gum type (processes for preparing chewing gums A23G 3/30) [2]
A61K 9/70	UGR1	. Web, sheet or filament bases (bandages, dressings or absorbent pads A61F 13/00) [2]
A61K 9/72	UGR1	. for smoking or inhaling [2]
A61K 31/00	HGR	Medicinal preparations containing organic active ingredients [2]
A61K 31/01	UGR1	. Hydrocarbons [2]
A61K 31/015	UGR2	. . carbocyclic [2]
A61K 31/02	UGR1	. Halogenated hydrocarbons [2]
A61K 31/025	UGR2	. . carbocyclic [2]
A61K 31/03	UGR3	. . . aromatic [2]
A61K 31/035	UGR2	. . having aliphatic unsaturation [2]
A61K 31/04	UGR1	. Nitro compounds [2]
A61K 31/045	UGR1	. Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates (hydroperoxides A61K 31/327) [2, 7]
A61K 31/047	UGR2	. . having two or more hydroxy groups, e.g. sorbitol [7]
A61K 31/05	UGR2	. . Phenols [2]
A61K 31/055	UGR3	. . . the aromatic ring being substituted by halogen [2]
A61K 31/06	UGR3	. . . the aromatic ring being substituted by nitro groups [2]
A61K 31/065	UGR2	. . Diphenyl-substituted acyclic alcohols [2]
A61K 31/07	UGR2	. . Retinol compounds, e.g. vitamin A (retinoic acids A61K 31/203) [2, 7]
A61K 31/075	UGR1	. Ethers or acetals [2]
A61K 31/08	UGR2	. . acyclic, e.g. paraformaldehyde [2]
A61K 31/085	UGR2	. . having an ether linkage to aromatic ring nuclear carbon [2]
A61K 31/09	UGR3	. . . having two or more such linkages [2]
A61K 31/095	UGR1	. Sulfur, selenium or tellurium compounds, e.g. thiols [2]
A61K 31/10	UGR2	. . Sulfides; Sulfoxides; Sulfones [2]
A61K 31/105	UGR2	. . Persulfides (thiuram disulfides A61K 31/145; thiosulfonic acids A61K 31/185) [2]
A61K 31/11	UGR1	. Aldehydes [2]
A61K 31/115	UGR2	. . Formaldehyde [2]
A61K 31/12	UGR1	. Ketones [2]
A61K 31/121	UGR2	. . acyclic [7]
A61K 31/122	UGR2	. . having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K_1_, anthralin [7]
A61K 31/125	UGR3	. . . Camphor; Nuclear substituted derivatives thereof [2]
A61K 31/13	UGR1	. Amines, e.g. amantadine (A61K 31/04 takes precedence) [2]
A61K 31/131	UGR2	. . acyclic [7]
A61K 31/132	UGR2	. . having two or more amino groups, e.g. spermidine, putrescine [7]
A61K 31/133	UGR2	. . having hydroxy groups, e.g. sphingosine [7]
A61K 31/135	UGR2	. . having aromatic rings, e.g. methadone [2, 7]
A61K 31/136	UGR3	. . . having the amino group directly attached to the aromatic ring, e.g. benzeneamine [7]
A61K 31/137	UGR3	. . . Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine [7]
A61K 31/138	UGR3	. . . Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K 31/165; pindolol A61K 31/404; timolol A61K 31/5377) [7]
A61K 31/14	UGR2	. . Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K 31/205) [2]
A61K 31/145	UGR2	. . having sulfur atoms, e.g. thiurams ( > N-C(S)-S-C(S)-N < or > N-C(S)-S-S-C(S)-N < ); Sulfinylamines (-N=SO); Sulfonylamines (-N=SO_2_) (isothioureas A61K 31/155) [2, 7]
A61K 31/15	UGR2	. . Oximes ( > C=N-O-); Hydrazines ( > N-N < ); Hydrazones ( > N-N=) [2]
A61K 31/155	UGR2	. . Amidines ( ), e.g. guanidine (H_2_N-C(=NH)-NH_2_), isourea (HN=C(OH)NH_2_), isothiourea (HN=C(SH)-NH_2_) [2]
A61K 31/16	UGR1	. Amides, e.g. hydroxamic acids [2]
A61K 31/164	UGR2	. . of a carboxylic acid with an aminoalcohol, e.g. ceramides [7]
A61K 31/165	UGR2	. . having aromatic rings, e.g. colchicine, atenolol, progabide [2]
A61K 31/166	UGR3	. . . having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol [7]
A61K 31/167	UGR3	. . . having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol [7]
A61K 31/17	UGR2	. . having the group > N-C(O)-N < or > N-C(S)-N < , e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K 31/155; sulfonylureas A61K 31/64) [2, 7]
A61K 31/175	UGR3	. . . having the group , > N-C(O)-N=N- or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof [2, 7]
A61K 31/18	UGR2	. . Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N-group A61K 31/63) [2]
A61K 31/185	UGR1	. Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K 31/16; peroxy acids A61K 31/327) [2, 7]
A61K 31/19	UGR2	. . Carboxylic acids, e.g. valproic acid (salicylic acid A61K 31/60) [2, 7]
A61K 31/191	UGR3	. . . Acyclic acids having two or more hydroxy groups, e.g. gluconic acid [7]
A61K 31/192	UGR3	. . . having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid [7]
A61K 31/194	UGR3	. . . having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid [7]
A61K 31/195	UGR3	. . . having an amino group [2, 7]
A61K 31/196	UGR4	. . . . the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil [7]
A61K 31/197	UGR4	. . . . the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid (carnitine A61K 31/205) [7]
A61K 31/198	UGR5	. . . . . Alpha-amino acids, e.g. alanine, edetic acid (EDTA) (betaine A61K 31/205; proline A61K 31/401; tryptophan A61K 31/405; histidine A61K 31/4172; peptides not degraded to individual amino acids A61K 38/00) [7]
A61K 31/20	UGR3	. . . having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid [2]
A61K 31/201	UGR4	. . . . having one or two double bonds, e.g. oleic or linoleic acid [7]
A61K 31/202	UGR4	. . . . having three or more double bonds, e.g. linolenic acid (eicosanoids, e.g. leukotrienes, A61K 31/557) [7]
A61K 31/203	UGR4	. . . . Retinoic acids [7]
A61K 31/205	UGR2	. . Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine [2]
A61K 31/21	UGR1	. Esters, e.g. nitroglycerine, selenocyanates [2]
A61K 31/215	UGR2	. . of carboxylic acids [2]
A61K 31/216	UGR3	. . . of acids having aromatic rings, e.g. benactizyne, clofibrate [7]
A61K 31/22	UGR3	. . . of acyclic acids, e.g. pravastatin [2]
A61K 31/221	UGR4	. . . . with compounds having an amino group, e.g. acetylcholine, acetylcarnitine [7]
A61K 31/222	UGR4	. . . . with compounds having aromatic groups, e.g. dipivefrine, ibopamine [7]
A61K 31/223	UGR4	. . . . of alpha-amino acids [7]
A61K 31/225	UGR4	. . . . Polycarboxylic acids [2]
A61K 31/23	UGR4	. . . . of acids having a carboxyl group bound to a chain of seven or more carbon atoms [2]
A61K 31/231	UGR5	. . . . . having one or two double bonds [7]
A61K 31/232	UGR5	. . . . . having three or more double bonds, e.g. etretinate [7]
A61K 31/235	UGR3	. . . having an aromatic ring attached to a carboxyl group [2]
A61K 31/24	UGR4	. . . . having an amino or nitro group [2]
A61K 31/245	UGR5	. . . . . Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K 31/60) [2]
A61K 31/25	UGR3	. . . with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol [2]
A61K 31/255	UGR2	. . of sulfoxy acids or sulfur analogues thereof [2]
A61K 31/26	UGR2	. . Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters [2, 7]
A61K 31/265	UGR2	. . of carbonic, thiocarbonic or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid [2]
A61K 31/27	UGR2	. . of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine [2]
A61K 31/275	UGR1	. Nitriles; Isonitriles [2]
A61K 31/277	UGR2	. . having a ring, e.g. verapamil [7]
A61K 31/28	UGR1	. Compounds containing heavy metals [2]
A61K 31/282	UGR2	. . Platinum compounds [7]
A61K 31/285	UGR2	. . Arsenic compounds [2]
A61K 31/29	UGR2	. . Antimony or bismuth compounds [2]
A61K 31/295	UGR2	. . Iron group metal compounds [2]
A61K 31/30	UGR2	. . Copper compounds [2]
A61K 31/305	UGR2	. . Mercury compounds [2]
A61K 31/31	UGR3	. . . containing nitrogen [2]
A61K 31/315	UGR2	. . Zinc compounds [2]
A61K 31/32	UGR2	. . Tin compounds [2]
A61K 31/325	UGR1	. Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof (thiurams A61K 31/145) [2]
A61K 31/327	UGR1	. Peroxy compounds, e.g. hydroperoxides, peroxides, peroxy acids [7]
A61K 31/33	UGR1	. Heterocyclic compounds [2]
A61K 31/335	UGR2	. . having oxygen as the only ring hetero atom, e.g. fungichromin [2]
A61K 31/336	UGR3	. . . having three-membered rings, e.g. oxirane, fumagillin [7]
A61K 31/337	UGR3	. . . having four-membered rings, e.g. taxol [7]
A61K 31/34	UGR3	. . . having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide [2]
A61K 31/341	UGR4	. . . . not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine [7]
A61K 31/343	UGR4	. . . . condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone [7]
A61K 31/345	UGR4	. . . . Nitrofurans (nitrofurantoin A61K 31/4178) [2, 7]
A61K 31/35	UGR3	. . . having six-membered rings with one oxygen as the only ring hetero atom [2]
A61K 31/351	UGR4	. . . . not condensed with another ring [7]
A61K 31/352	UGR4	. . . . condensed with carbocyclic rings, e.g. cannabinols, methantheline [7]
A61K 31/353	UGR5	. . . . . 3,4-Dihydrobenzopyrans, e.g. chroman, catechin [7]
A61K 31/355	UGR6	. . . . . . Tocopherols, e.g. vitamin E [2]
A61K 31/357	UGR3	. . . having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel [7]
A61K 31/36	UGR4	. . . . Compounds containing methylenedioxyphenyl groups, e.g. sesamin [2]
A61K 31/365	UGR3	. . . Lactones [2]
A61K 31/366	UGR4	. . . . having six-membered rings, e.g. delta-lactones [7]
A61K 31/37	UGR5	. . . . . Coumarins, e.g. psoralen [2]
A61K 31/375	UGR4	. . . . Ascorbic acid, i.e. vitamin C; Salts thereof [2]
A61K 31/38	UGR2	. . having sulfur as a ring hetero atom [2]
A61K 31/381	UGR3	. . . having five-membered rings [7]
A61K 31/382	UGR3	. . . having six-membered rings, e.g. thioxanthenes (thiothixene A61K 31/496) [7]
A61K 31/385	UGR3	. . . having two or more sulfur atoms in the same ring [2]
A61K 31/39	UGR3	. . . having oxygen atoms in the same ring [2]
A61K 31/395	UGR2	. . having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins (rifampin A61K 31/496) [2, 7]
A61K 31/396	UGR3	. . . having three-membered rings, e.g. aziridine [7]
A61K 31/397	UGR3	. . . having four-membered rings, e.g. azetidine [7]
A61K 31/40	UGR3	. . . having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil [2]
A61K 31/401	UGR4	. . . . Proline; Derivatives thereof, e.g. captopril [7]
A61K 31/4015	UGR4	. . . . having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide [7]
A61K 31/402	UGR4	. . . . 1-aryl-substituted, e.g. piretanide [7]
A61K 31/4025	UGR4	. . . . not condensed and containing further heterocyclic rings, e.g. cromakalim [7]
A61K 31/403	UGR4	. . . . condensed with carbocyclic rings, e.g. carbazole [7]
A61K 31/4035	UGR5	. . . . . Isoindoles, e.g. phthalimide [7]
A61K 31/404	UGR5	. . . . . Indoles, e.g. pindolol [7]
A61K 31/4045	UGR6	. . . . . . Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin [7]
A61K 31/405	UGR6	. . . . . . Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin [2]
A61K 31/407	UGR4	. . . . condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine [7]
A61K 31/409	UGR4	. . . . having four such rings, e.g. porphine derivatives, bilirubin, biliverdine (hemin, hematin A61K 31/555) [7]
A61K 31/41	UGR3	. . . having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole [2]
A61K 31/415	UGR4	. . . . 1,2-Diazoles [2, 7]
A61K 31/4152	UGR5	. . . . . having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone [7]
A61K 31/4155	UGR5	. . . . . not condensed and containing further heterocyclic rings [7]
A61K 31/416	UGR5	. . . . . condensed with carbocyclic ring systems, e.g. indazole [7]
A61K 31/4162	UGR5	. . . . . condensed with heterocyclic ring systems [7]
A61K 31/4164	UGR4	. . . . 1,3-Diazoles [7]
A61K 31/4166	UGR5	. . . . . having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin [7]
A61K 31/4168	UGR5	. . . . . having a nitrogen atom attached in position 2, e.g. clonidine [7]
A61K 31/417	UGR5	. . . . . Imidazole-alkylamines, e.g. histamine, phentolamine [7]
A61K 31/4172	UGR5	. . . . . Imidazole-alkanecarboxylic acids, e.g. histidine [7]
A61K 31/4174	UGR5	. . . . . Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole [7]
A61K 31/4178	UGR5	. . . . . not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin [7]
A61K 31/4184	UGR5	. . . . . condensed with carbocyclic rings, e.g. benzimidazoles [7]
A61K 31/4188	UGR5	. . . . . condensed with heterocyclic ring systems, e.g. biotin, sorbinil [7]
A61K 31/4192	UGR4	. . . . 1,2,3-Triazoles [7]
A61K 31/4196	UGR4	. . . . 1,2,4-Triazoles [7]
A61K 31/42	UGR4	. . . . Oxazoles [2, 7]
A61K 31/421	UGR5	. . . . . 1,3-Oxazoles, e.g. pemoline, trimethadione [7]
A61K 31/422	UGR5	. . . . . not condensed and containing further heterocyclic rings [7]
A61K 31/423	UGR5	. . . . . condensed with carbocyclic rings [7]
A61K 31/424	UGR5	. . . . . condensed with heterocyclic ring systems, e.g. clavulanic acid [7]
A61K 31/4245	UGR4	. . . . Oxadiazoles [7]
A61K 31/425	UGR4	. . . . Thiazoles [2, 7]
A61K 31/426	UGR5	. . . . . 1,3-Thiazoles [7]
A61K 31/427	UGR5	. . . . . not condensed and containing further heterocyclic rings [7]
A61K 31/428	UGR5	. . . . . condensed with carbocyclic rings [7]
A61K 31/429	UGR5	. . . . . condensed with heterocyclic ring systems [7]
A61K 31/43	UGR6	. . . . . . Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems [2, 6]
A61K 31/431	UGR7	. . . . . . . containing further heterocyclic ring systems, e.g. ticarcillin, azlocillin, oxacillin [7]
A61K 31/433	UGR4	. . . . Thiadiazoles [7]
A61K 31/435	UGR3	. . . having six-membered rings with one nitrogen as the only ring hetero atom [2]
A61K 31/4353	UGR4	. . . . ortho- or peri-condensed with heterocyclic ring systems [7]
A61K 31/4355	UGR5	. . . . . the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom [7]
A61K 31/436	UGR5	. . . . . the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin [7]
A61K 31/4365	UGR5	. . . . . the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine [7]
A61K 31/437	UGR5	. . . . . the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline [7]
A61K 31/4375	UGR5	. . . . . the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine [7]
A61K 31/438	UGR4	. . . . the ring being spiro-condensed with carbocyclic or heterocyclic ring systems [7]
A61K 31/439	UGR4	. . . . the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K 31/46) [7]
A61K 31/44	UGR4	. . . . Non-condensed pyridines; Hydrogenated derivatives thereof [2, 7]
A61K 31/4402	UGR5	. . . . . only substituted in position 2, e.g. pheniramine, bisacodyl [7]
A61K 31/4406	UGR5	. . . . . only substituted in position 3, e.g. zimeldine (nicotinic acid A61K 31/455) [7]
A61K 31/4409	UGR5	. . . . . only substituted in position 4, e.g. isoniazid, iproniazid [7]
A61K 31/4412	UGR5	. . . . . having oxo groups directly attached to the heterocyclic ring [7]
A61K 31/4415	UGR5	. . . . . Pyridoxine, i.e.vitamin B_6_ (pyridoxal phosphate A61K 31/675) [7]
A61K 31/4418	UGR5	. . . . . having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine [7]
A61K 31/4422	UGR5	. . . . . 1,4-Dihydropyridines, e.g. nifedipine, nicardipine [7]
A61K 31/4425	UGR5	. . . . . Pyridinium derivatives, e.g. pralidoxime, pyridostigmine [7]
A61K 31/4427	UGR5	. . . . . containing further heterocyclic ring systems [7]
A61K 31/443	UGR6	. . . . . . containing a five-membered ring with oxygen as a ring hetero atom [7]
A61K 31/4433	UGR6	. . . . . . containing a six-membered ring with oxygen as a ring hetero atom [7]
A61K 31/4436	UGR6	. . . . . . containing a heterocyclic ring having sulfur as a ring hetero atom [7]
A61K 31/4439	UGR6	. . . . . . containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K 31/465) [7]
A61K 31/444	UGR6	. . . . . . containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone [7]
A61K 31/445	UGR5	. . . . . Non-condensed piperidines, e.g. piperocaine [2, 7]
A61K 31/4453	UGR6	. . . . . . only substituted in position 1, e.g. propipocaine, diperodon [7]
A61K 31/4458	UGR6	. . . . . . only substituted in position 2, e.g. methylphenidate [7]
A61K 31/4462	UGR6	. . . . . . only substituted in position 3 [7]
A61K 31/4465	UGR6	. . . . . . only substituted in position 4 [7]
A61K 31/4468	UGR6	. . . . . . having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl [7]
A61K 31/45	UGR6	. . . . . . having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide [2, 7]
A61K 31/451	UGR6	. . . . . . having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine [7]
A61K 31/4515	UGR6	. . . . . . having a butyrophenone group in position 1, e.g. haloperidol (pipamperone A61K 31/4545) [7]
A61K 31/452	UGR6	. . . . . . Piperidinium derivatives (pancuronium A61K 31/58) [7]
A61K 31/4523	UGR6	. . . . . . containing further heterocyclic ring systems [7]
A61K 31/4525	UGR7	. . . . . . . containing a five-membered ring with oxygen as a ring hetero atom [7]
A61K 31/453	UGR7	. . . . . . . containing a six-membered ring with oxygen as a ring hetero atom [7]
A61K 31/4535	UGR7	. . . . . . . containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen [7]
A61K 31/454	UGR7	. . . . . . . containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone [7]
A61K 31/4545	UGR7	. . . . . . . containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine [7]
A61K 31/455	UGR5	. . . . . Nicotinic acid, i.e. niacin; Derivatives thereof, e.g. esters, amides [2]
A61K 31/46	UGR4	. . . . 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine [2]
A61K 31/465	UGR4	. . . . Nicotine; Derivatives thereof [2]
A61K 31/47	UGR4	. . . . Quinolines; Isoquinolines [2]
A61K 31/4704	UGR5	. . . . . 2-Quinolinones, e.g. carbostyril [7]
A61K 31/4706	UGR5	. . . . . 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine [7]
A61K 31/4709	UGR5	. . . . . Non-condensed quinolines containing further heterocyclic rings [7]
A61K 31/472	UGR5	. . . . . Non-condensed isoquinolines, e.g. papaverine [7]
A61K 31/4725	UGR6	. . . . . . containing further heterocyclic rings [7]
A61K 31/473	UGR5	. . . . . ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines [7]
A61K 31/4738	UGR5	. . . . . ortho- or peri-condensed with heterocyclic ring systems [7]
A61K 31/4741	UGR6	. . . . . . condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline [7]
A61K 31/4743	UGR6	. . . . . . condensed with ring systems having sulfur as a ring hetero atom [7]
A61K 31/4745	UGR6	. . . . . . condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines (yohimbine derivatives, vinblastine A61K 31/475; ergoline derivatives A61K 31/48) [7]
A61K 31/4747	UGR5	. . . . . spiro-condensed [7]
A61K 31/4748	UGR5	. . . . . forming part of bridged ring systems (strychnine A61K 31/475; morphinan derivatives A61K 31/485) [7]
A61K 31/475	UGR5	. . . . . having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K 31/4375) [2, 7]
A61K 31/48	UGR5	. . . . . Ergoline derivatives, e.g. lysergic acid, ergotamine [2, 7]
A61K 31/485	UGR5	. . . . . Morphinan derivatives, e.g. morphine, codeine [2, 7]
A61K 31/49	UGR5	. . . . . Cinchonan derivatives, e.g. quinine [2, 7]
A61K 31/495	UGR3	. . . having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine (A61K 31/48 takes precedence) [2]
A61K 31/496	UGR4	. . . . Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene [7]
A61K 31/4965	UGR4	. . . . Non-condensed pyrazines [7]
A61K 31/497	UGR5	. . . . . containing further heterocyclic rings [7]
A61K 31/498	UGR4	. . . . Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine [7]
A61K 31/4985	UGR4	. . . . Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems [7]
A61K 31/499	UGR4	. . . . Spiro-condensed pyrazines or piperazines [7]
A61K 31/4995	UGR4	. . . . Pyrazines or piperazines forming part of bridged ring systems [7]
A61K 31/50	UGR4	. . . . Pyridazines; Hydrogenated pyridazines [2, 7]
A61K 31/501	UGR5	. . . . . not condensed and containing further heterocyclic rings [7]
A61K 31/502	UGR5	. . . . . ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine [7]
A61K 31/5025	UGR5	. . . . . ortho- or peri-condensed with heterocyclic ring systems [7]
A61K 31/503	UGR5	. . . . . spiro-condensed [7]
A61K 31/504	UGR5	. . . . . forming part of bridged ring systems [7]
A61K 31/505	UGR4	. . . . Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim [2, 7]
A61K 31/506	UGR5	. . . . . not condensed and containing further heterocyclic rings [7]
A61K 31/51	UGR6	. . . . . . Thiamines, e.g. vitamin B_1_ [2]
A61K 31/513	UGR5	. . . . . having oxo groups directly attached to the heterocyclic ring, e.g. cytosine [7]
A61K 31/515	UGR6	. . . . . . Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital [2]
A61K 31/517	UGR5	. . . . . ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine [7]
A61K 31/519	UGR5	. . . . . ortho- or peri-condensed with heterocyclic rings [7]
A61K 31/52	UGR6	. . . . . . Purines, e.g. adenine [2, 7]
A61K 31/522	UGR7	. . . . . . . having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir [7]
A61K 31/525	UGR6	. . . . . . Isoalloxazines, e.g. riboflavins, vitamin B_2_ [2]
A61K 31/527	UGR5	. . . . . spiro-condensed [7]
A61K 31/529	UGR5	. . . . . forming part of bridged ring systems [7]
A61K 31/53	UGR3	. . . having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K 31/555) [2]
A61K 31/535	UGR3	. . . having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines [2]
A61K 31/5355	UGR4	. . . . Non-condensed oxazines containing further heterocyclic rings [7]
A61K 31/536	UGR4	. . . . ortho- or peri-condensed with carbocyclic ring systems [7]
A61K 31/5365	UGR4	. . . . ortho- or peri-condensed with heterocyclic ring systems [7]
A61K 31/537	UGR4	. . . . spiro-condensed or forming part of bridged ring systems [7]
A61K 31/5375	UGR4	. . . . 1,4-Oxazines, e.g. morpholine [7]
A61K 31/5377	UGR5	. . . . . not condensed and containing further heterocyclic rings, e.g. timolol [7]
A61K 31/538	UGR5	. . . . . ortho- or peri-condensed with carbocyclic ring systems [7]
A61K 31/5383	UGR5	. . . . . ortho- or peri-condensed with heterocyclic ring systems [7]
A61K 31/5386	UGR5	. . . . . spiro-condensed or forming part of bridged ring systems [7]
A61K 31/539	UGR4	. . . . having two or more oxygen atoms in the same ring, e.g dioxazines [7]
A61K 31/5395	UGR4	. . . . having two or more nitrogen atoms in the same ring, e.g. oxadiazines [7]
A61K 31/54	UGR3	. . . having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame [2]
A61K 31/541	UGR4	. . . . Non-condensed thiazines containing further heterocyclic rings [7]
A61K 31/5415	UGR4	. . . . ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam [7]
A61K 31/542	UGR4	. . . . ortho- or peri-condensed with heterocyclic ring systems [7]
A61K 31/545	UGR5	. . . . . Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine [2, 6]
A61K 31/546	UGR6	. . . . . . containing further heterocyclic rings, e.g. cephalothin [7]
A61K 31/547	UGR4	. . . . spiro-condensed or forming part of bridged ring systems [7]
A61K 31/548	UGR4	. . . . having two or more sulfur atoms in the same ring [7]
A61K 31/549	UGR4	. . . . having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide [7]
A61K 31/55	UGR3	. . . having seven-membered rings, e.g. azelastine, pentylenetetrazole [2]
A61K 31/551	UGR4	. . . . having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep [7]
A61K 31/5513	UGR5	. . . . . 1,4-Benzodiazepines, e.g. diazepam [7]
A61K 31/5517	UGR6	. . . . . . condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam [7]
A61K 31/553	UGR4	. . . . having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine [7]
A61K 31/554	UGR4	. . . . having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem [7]
A61K 31/555	UGR2	. . containing heavy metals, e.g. hemin, hematin, melarsoprol [2]
A61K 31/557	UGR1	. Eicosanoids, e.g. leukotrienes [3, 7]
A61K 31/5575	UGR2	. . having a cyclopentane ring, e.g. prostaglandin E_2_, prostaglandin F_2-alpha_ [7]
A61K 31/5578	UGR2	. . having a pentalene ring system, e.g. carbacyclin, iloprost [7]
A61K 31/558	UGR2	. . having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes [7]
A61K 31/5585	UGR3	. . . having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin [7]
A61K 31/559	UGR2	. . having heterocyclic rings containing hetero atoms other than oxygen [7]
A61K 31/56	UGR1	. Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids [4, 7]
A61K 31/565	UGR2	. . not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol [2]
A61K 31/566	UGR3	. . . having an oxo group in position 17, e.g. oestrone [7]
A61K 31/567	UGR3	. . . substituted in position 17 alpha, e.g. mestranol, norethandrolone [7]
A61K 31/568	UGR3	. . . substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone [7]
A61K 31/5685	UGR4	. . . . having an oxo group in position 17, e.g. androsterone [7]
A61K 31/569	UGR4	. . . . substituted in position 17 alpha, e.g. ethisterone [7]
A61K 31/57	UGR2	. . substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone [2]
A61K 31/573	UGR3	. . . substituted in position 21, e.g. cortisone, dexamethasone, prednisone [7]
A61K 31/575	UGR2	. . substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol [2]
A61K 31/58	UGR2	. . containing heterocyclic rings, e.g. aldosterone, danazol, stanozolol, pancuronium, digitogenin (digitoxin A61K 31/704) [2, 7]
A61K 31/585	UGR3	. . . containing lactone rings, e.g. oxandrolone, bufalin [2]
A61K 31/59	UGR1	. Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems [2]
A61K 31/592	UGR2	. . 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D_2_ [7]
A61K 31/593	UGR2	. . 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D_3_ [7]
A61K 31/595	GEL	(covered by A61K 31/59)
A61K 31/60	UGR1	. Salicylic acid; Derivatives thereof [2]
A61K 31/603	UGR2	. . having further aromatic rings, e.g. diflunisal [7]
A61K 31/605	GEL	(transferred to A61K 31/60;  to ; A61K 31/621)
A61K 31/606	UGR2	. . having amino groups [7]
A61K 31/609	UGR2	. . Amides, e.g. salicylamide [7]
A61K 31/61	GEL	(transferred to A61K 31/60;  to ; A61K 31/621)
A61K 31/612	UGR2	. . having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid (fosfosal A61K 31/661) [7]
A61K 31/615	GEL	(transferred to A61K 31/60;  to ; A61K 31/621)
A61K 31/616	UGR3	. . . by carboxylic acids, e.g. acetylsalicylic acid [7]
A61K 31/618	UGR2	. . having the carboxyl group in position 1 esterified, e.g. salsalate [7]
A61K 31/62	GEL	(transferred to A61K 31/60;  to ; A61K 31/621)
A61K 31/621	UGR3	. . . having the hydroxy group in position 2 esterified, e.g. benorylate [7]
A61K 31/625	UGR2	. . having heterocyclic substituents, e.g. 4-salicyloylmorpholine (sulfasalazine A61K 31/635) [2, 7]
A61K 31/63	UGR1	. Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide [2]
A61K 31/635	UGR2	. . having a heterocyclic ring, e.g. sulfasalazine [2]
A61K 31/64	UGR1	. Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide [2]
A61K 31/645	GEL	(covered by A61K 31/00)
A61K 31/65	UGR1	. Tetracyclines [2]
A61K 31/655	UGR1	. Azo (-N=N-), diazo (=N_2_), azoxy (> N-O-N < or N(=O)-N <); azido (-N_3_) or diazoamino (-N=N-N < ) compounds [2]
A61K 31/66	UGR1	. Phosphorus compounds [2]
A61K 31/661	UGR2	. . Phosphorus acids or esters thereof not having P-C bonds, e.g. fosfosal, dichlorvos, malathion [7]
A61K 31/6615	UGR3	. . . Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid [7]
A61K 31/662	UGR2	. . Phosphorus acids or esters thereof having P-C bonds, e.g. foscarnet, trichlorfon [7]
A61K 31/663	UGR3	. . . Compounds having two or more phosphorus acid groups or esters thereof , e.g. clodronic acid, pamidronic acid [7]
A61K 31/664	UGR2	. . Amides of phosphorus acids [7]
A61K 31/665	UGR2	. . having oxygen as a ring hetero atom, e.g. fosfomycin [2]
A61K 31/67	UGR2	. . having sulfur as a ring hetero atom [2]
A61K 31/675	UGR2	. . having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate [2]
A61K 31/68	GEL	(transferred to A61K 31/714)
A61K 31/683	UGR2	. . Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols [7]
A61K 31/685	UGR3	. . . one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin [2, 7]
A61K 31/688	UGR3	. . . both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins [7]
A61K 31/69	UGR1	. Boron compounds [2]
A61K 31/695	UGR1	. Silicon compounds [2]
A61K 31/70	UGR1	. Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K 31/047) [2, 7]
A61K 31/7004	UGR2	. . Monosaccharides having only carbon, hydrogen and oxygen atoms [7]
A61K 31/7008	UGR2	. . Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine [7]
A61K 31/7012	UGR2	. . Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid (gluconic acid A61K 31/191; ascorbic acid A61K 31/375) [7]
A61K 31/7016	UGR2	. . Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K 31/7032) [7]
A61K 31/702	UGR2	. . Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages [7]
A61K 31/7024	UGR2	. . Esters of saccharides [7]
A61K 31/7028	UGR2	. . Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages [7]
A61K 31/7032	UGR3	. . . attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides [7]
A61K 31/7034	UGR3	. . . attached to a carbocyclic compound, e.g. phloridzin [7]
A61K 31/7036	UGR4	. . . . having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins [7]
A61K 31/704	UGR4	. . . . attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin [7]
A61K 31/7042	UGR2	. . Compounds having saccharide radicals and heterocyclic rings [7]
A61K 31/7048	UGR3	. . . having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin [7]
A61K 31/705	GEL	(transferred to A61K 31/704)
A61K 31/7052	UGR3	. . . having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides [7]
A61K 31/7056	UGR4	. . . . containing five-membered rings with nitrogen as a ring hetero atom [7]
A61K 31/706	UGR4	. . . . containing six-membered rings with nitrogen as a ring hetero atom [7]
A61K 31/7064	UGR5	. . . . . containing condensed or non-condensed pyrimidines [7]
A61K 31/7068	UGR6	. . . . . . having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid [7]
A61K 31/7072	UGR7	. . . . . . . having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine [7]
A61K 31/7076	UGR6	. . . . . . containing purines, e.g. adenosine, adenylic acid [7]
A61K 31/708	UGR7	. . . . . . . having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid [7]
A61K 31/7084	UGR2	. . Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide [7]
A61K 31/7088	UGR2	. . Compounds having three or more nucleosides or nucleotides [7]
A61K 31/71	GEL	(transferred to A61K 31/70;  to ; A61K 31/714)
A61K 31/7105	UGR3	. . . Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links [7]
A61K 31/711	UGR3	. . . Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links [7]
A61K 31/7115	UGR3	. . . Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine [7]
A61K 31/712	UGR3	. . . Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose [7]
A61K 31/7125	UGR3	. . . Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters [7]
A61K 31/713	UGR3	. . . Double-stranded nucleic acids or oligonucleotides [7]
A61K 31/7135	UGR2	. . Compounds containing heavy metals [7]
A61K 31/714	UGR3	. . . Cobalamins, e.g. cyanocobalamin, vitamin B_12_ [7]
A61K 31/715	UGR2	. . Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters [2]
A61K 31/716	UGR3	. . . Glucans [7]
A61K 31/717	UGR4	. . . . Celluloses [7]
A61K 31/718	UGR4	. . . . Starch or degraded starch, e.g. amylose, amylopectin [7]
A61K 31/719	UGR4	. . . . Pullulans [7]
A61K 31/72	GEL	(covered by A61K 31/715)
A61K 31/721	UGR4	. . . . Dextrans [7]
A61K 31/722	UGR4	. . . . Chitin; Chitosan [7]
A61K 31/723	UGR4	. . . . Xanthans [7]
A61K 31/724	UGR4	. . . . Cyclodextrins [7]
A61K 31/725	GEL	(covered by A61K 31/715)
A61K 31/726	UGR3	. . . Glycosaminoglycans, i.e. mucopolysaccharides (chondroitin sulfate, dermatan sulfate A61K 31/737) [7]
A61K 31/727	UGR4	. . . . Heparin; Heparan [7]
A61K 31/728	UGR4	. . . . Hyaluronic acid [7]
A61K 31/729	UGR3	. . . Agar; Agarose; Agaropectin [7]
A61K 31/73	GEL	(covered by A61K 31/715)
A61K 31/731	UGR3	. . . Carrageenans [7]
A61K 31/732	UGR3	. . . Pectin [7]
A61K 31/733	UGR3	. . . Fructosans, e.g. inulin [7]
A61K 31/734	UGR3	. . . Alginic acid [7]
A61K 31/735	GEL	(covered by A61K 31/715)
A61K 31/736	UGR3	. . . Glucomannans or galactomannans, e.g locust bean gum, guar gum [7]
A61K 31/737	UGR3	. . . Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K 31/727 takes precedence) [7]
A61K 31/738	UGR3	. . . Cross-linked polysaccharides [7]
A61K 31/739	UGR3	. . . Lipopolysaccharides [7]
A61K 31/74	UGR1	. Synthetic polymeric materials [2]
A61K 31/745	UGR2	. . Polymers of hydrocarbons [2]
A61K 31/75	UGR3	. . . of ethene [2]
A61K 31/755	UGR2	. . Polymers containing halogen [2]
A61K 31/76	UGR3	. . . of vinyl chloride [2]
A61K 31/765	UGR2	. . Polymers containing oxygen [2]
A61K 31/77	UGR3	. . . of oxiranes [2]
A61K 31/775	UGR3	. . . Phenolic resins [2]
A61K 31/78	UGR3	. . . of acrylic acid or derivatives thereof [2]
A61K 31/785	UGR2	. . Polymers containing nitrogen [2]
A61K 31/787	UGR3	. . . containing heterocyclic rings having nitrogen as a ring hetero atom [7]
A61K 31/79	UGR4	. . . . Polymers of vinyl pyrrolidone [2]
A61K 31/795	UGR2	. . Polymers containing sulfur [2]
A61K 31/80	UGR2	. . Polymers containing hetero atoms not provided for in groups A61K 31/755 to A61K 31/795 [2]
A61K 33/00	HGR	Medicinal preparations containing inorganic active ingredients [2]
A61K 33/02	UGR1	. Ammonia; Compounds thereof [2]
A61K 33/04	UGR1	. Sulfur, selenium or tellurium; Compounds thereof [2]
A61K 33/06	UGR1	. Aluminium, calcium or magnesium; Compounds thereof [2]
A61K 33/08	UGR2	. . Oxides; Hydroxides [2]
A61K 33/10	UGR2	. . Carbonates; Bicarbonates [2]
A61K 33/12	UGR2	. . Magnesium silicate [2]
A61K 33/14	UGR1	. Alkali metal chlorides; Alkaline earth metal chlorides [2]
A61K 33/16	UGR1	. Fluorine compounds [2]
A61K 33/18	UGR1	. Iodine; Compounds thereof [2]
A61K 33/20	UGR1	. Elemental chlorine; Inorganic compounds releasing chlorine [2]
A61K 33/22	UGR1	. Boron compounds [2]
A61K 33/24	UGR1	. Heavy metals; Compounds thereof [2]
A61K 33/26	UGR2	. . Iron; Compounds thereof [2]
A61K 33/28	UGR2	. . Mercury; Compounds thereof [2]
A61K 33/30	UGR2	. . Zinc; Compounds thereof [2]
A61K 33/32	UGR2	. . Manganese; Compounds thereof [2]
A61K 33/34	UGR2	. . Copper; Compounds thereof [2]
A61K 33/36	UGR2	. . Arsenic; Compounds thereof [2]
A61K 33/38	UGR2	. . Silver; Compounds thereof [2]
A61K 33/40	UGR1	. Peroxides [2]
A61K 33/42	UGR1	. Phosphorus; Compounds thereof [2]
A61K 33/44	UGR1	. Elemental carbon, e.g. charcoal, carbon black [2]
A61K 35/00	HGR	Medicinal preparations containing material or reaction products thereof with undetermined constitution [2]
A61K 35/02	UGR1	. from inanimate materials [2]
A61K 35/04	UGR2	. . Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate, e.g. IchthyolR [2]
A61K 35/06	UGR3	. . . Mineral oils [2]
A61K 35/08	UGR2	. . Mineral waters [2]
A61K 35/10	UGR2	. . Peat; Amber [2]
A61K 35/12	UGR1	. Materials from mammals or birds [2]
A61K 35/14	UGR2	. . Blood [2]
A61K 35/16	UGR3	. . . Plasma; Serum [2]
A61K 35/18	UGR3	. . . Erythrocytes [2]
A61K 35/20	UGR2	. . Milk; Colostrum [2]
A61K 35/22	UGR2	. . Urine; Urinary system [2]
A61K 35/23	UGR3	. . . Kidney [3]
A61K 35/24	UGR2	. . Mucus; Mucous glands; Bursa; Arthral fluid; Excreta; Spinal fluid [2]
A61K 35/26	UGR2	. . Lymph; Lymph-glands; Thymus [2]
A61K 35/28	UGR2	. . Marrow; Spleen [2]
A61K 35/30	UGR2	. . Nerves; Brain [2]
A61K 35/32	UGR2	. . Bones; Tendons; Teeth; Cartilage (marrow A61K 35/28) [2]
A61K 35/34	UGR2	. . Muscles; Heart [2]
A61K 35/36	UGR2	. . Skin; Hair; Nails; Sebaceous glands; Cerumen [4]
A61K 35/37	UGR2	. . Digestive system [3]
A61K 35/38	UGR3	. . . Stomach; Intestine [3]
A61K 35/39	UGR3	. . . Pancreas [3]
A61K 35/407	UGR3	. . . Liver [3]
A61K 35/413	UGR3	. . . Bile [3]
A61K 35/42	UGR2	. . Lungs [2]
A61K 35/44	UGR2	. . Eyes; Vessels; Umbilical cord [2]
A61K 35/48	UGR2	. . Reproductive organs; Embryos [2]
A61K 35/50	UGR3	. . . Placenta; Amniotic fluid [2]
A61K 35/52	UGR3	. . . Sperm [2]
A61K 35/54	UGR3	. . . Ovary; Eggs; Embryos [2]
A61K 35/55	UGR2	. . Glands not provided for in one of the preceding subgroups of this main group [3]
A61K 35/56	UGR1	. Materials from animals other than mammals or birds [2]
A61K 35/58	UGR2	. . Snakes (antigens A61K 39/38) [2]
A61K 35/60	UGR2	. . Fish (vitamin A A61K 31/07; vitamin D A61K 31/59) [2]
A61K 35/62	UGR2	. . Leeches [2]
A61K 35/64	UGR2	. . Insects, e.g. royal jelly [2]
A61K 35/66	UGR1	. Materials from micro-organisms [2]
A61K 35/68	UGR2	. . Protozoa [2]
A61K 35/70	UGR2	. . Lower fungi [2]
A61K 35/72	UGR2	. . Yeasts [2]
A61K 35/74	UGR2	. . Bacteria [2]
A61K 35/76	UGR2	. . Viruses [2]
A61K 35/78	UGR1	. Materials from plants [2]
A61K 35/80	UGR2	. . Algae [2]
A61K 35/82	UGR2	. . Lichens [2]
A61K 35/84	UGR2	. . Higher fungi [2]
A61K 38/00	HGR	Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K 31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K 31/00; ergoline-based peptides A61K 31/48; containing macromolecular compounds having statistically distributed amino acid units A61K 31/74; medicinal preparations containing antigens or antibodies A61K 39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K 47/00) [6]
A61K 38/01	UGR1	. Hydrolysed proteins; Derivatives thereof [6]
A61K 38/02	UGR1	. Peptides of undefined number of amino acids; Derivatives thereof [6]
A61K 38/03	UGR1	. Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof [6]
A61K 38/04	UGR1	. Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof (gastrins A61K 38/16 , somatostatins A61K 38/31 , melanotropins A61K 38/34) [6]
A61K 38/05	UGR2	. . Dipeptides [6]
A61K 38/06	UGR2	. . Tripeptides [6]
A61K 38/07	UGR2	. . Tetrapeptides [6]
A61K 38/08	UGR2	. . Peptides having 5 to 11 amino acids [6]
A61K 38/09	UGR3	. . . Luteinising hormone-releasing hormone (LHRH); Related peptides [6]
A61K 38/10	UGR2	. . Peptides having 12 to 20 amino acids [6]
A61K 38/11	UGR3	. . . Oxytocins; Vasopressins; Related peptides [6]
A61K 38/12	UGR2	. . Cyclic peptides [6]
A61K 38/13	UGR3	. . . Cyclosporins [6]
A61K 38/14	UGR2	. . Peptides containing saccharide radicals; Derivatives thereof [6]
A61K 38/15	UGR2	. . Depsipeptides; Derivatives thereof [6]
A61K 38/16	UGR1	. Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof [6]
A61K 38/17	UGR2	. . from animals; from humans [6]
A61K 38/18	UGR3	. . . Growth factors; Growth regulators [6]
A61K 38/19	UGR3	. . . Cytokines; Lymphokines; Interferons [6]
A61K 38/20	UGR4	. . . . Interleukins [6]
A61K 38/21	UGR4	. . . . Interferons [6]
A61K 38/22	UGR3	. . . Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K 38/33 , e.g. corticotropin A61K 38/35) [6]
A61K 38/23	UGR4	. . . . Calcitonins [6]
A61K 38/24	UGR4	. . . . Follicle-stimulating hormone (FSH); Chorionic gonadotropins, e.g. HCG; Luteinising hormone (LH); Thyroid-stimulating hormone (TSH) [6]
A61K 38/25	UGR4	. . . . Growth hormone-releasing factor (GH-RF) (Somatoliberin) [6]
A61K 38/26	UGR4	. . . . Glucagons [6]
A61K 38/27	UGR4	. . . . Growth hormone (GH) (Somatotropin) [6]
A61K 38/28	UGR4	. . . . Insulins [6]
A61K 38/29	UGR4	. . . . Parathyroid hormone (parathormone); Parathyroid hormone-related peptides [6]
A61K 38/30	UGR4	. . . . Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2 [6]
A61K 38/31	UGR4	. . . . Somatostatins [6]
A61K 38/32	UGR4	. . . . Thymopoietins [6]
A61K 38/33	UGR3	. . . derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin [6]
A61K 38/34	UGR4	. . . . Melanocyte stimulating hormone (MSH), e.g. alpha- or beta-melanotropin [6]
A61K 38/35	UGR4	. . . . Corticotropin (ACTH) [6]
A61K 38/36	UGR3	. . . Blood coagulation or fibrinolysis factors [6]
A61K 38/37	UGR4	. . . . Factors VIII [6]
A61K 38/38	UGR3	. . . Albumins [6]
A61K 38/39	UGR3	. . . Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG) [6]
A61K 38/40	UGR3	. . . Transferrins, e.g. lactoferrins, ovotransferrins [6]
A61K 38/41	UGR2	. . Porphyrin- or corrin-ring-containing peptides [6]
A61K 38/42	UGR3	. . . Haemoglobins; Myoglobins [6]
A61K 38/43	UGR2	. . Enzymes; Proenzymes; Derivatives thereof [6]
A61K 38/44	UGR3	. . . Oxidoreductases (1) [6]
A61K 38/45	UGR3	. . . Transferases (2) [6]
A61K 38/46	UGR3	. . . Hydrolases (3) [6]
A61K 38/47	UGR4	. . . . acting on glycosyl compounds (3.2), e.g. cellulases, lactases [6]
A61K 38/48	UGR4	. . . . acting on peptide bonds (3.4) [6]
A61K 38/49	UGR5	. . . . . Urokinase; Tissue plasminogen activator [6]
A61K 38/50	UGR4	. . . . acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase [6]
A61K 38/51	UGR3	. . . Lyases (4) [6]
A61K 38/52	UGR3	. . . Isomerases (5) [6]
A61K 38/53	UGR3	. . . Ligases (6) [6]
A61K 38/54	UGR3	. . . Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K 38/44 to A61K 38/46 or A61K 38/51 to A61K 38/53 [6]
A61K 38/55	UGR2	. . Protease inhibitors [6]
A61K 38/56	UGR3	. . . from plants [6]
A61K 38/57	UGR3	. . . from animals; from humans [6]
A61K 38/58	UGR4	. . . . from leeches, e.g. hirudin, eglin [6]
A61K 39/00	HGR	Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N 33/53) [2]
A61K 39/002	UGR1	. Protozoa antigens [3]
A61K 39/005	UGR2	. . Trypanosoma antigens [3]
A61K 39/008	UGR2	. . Leishmania antigens [3]
A61K 39/012	UGR2	. . Coccidia antigens [3]
A61K 39/015	UGR2	. . Hemosporidia antigens, e.g. Plasmodium antigens [3]
A61K 39/018	UGR3	. . . Babesia antigens, e.g. Theileria antigens [3]
A61K 39/02	UGR1	. Bacterial antigens [2]
A61K 39/04	UGR2	. . Mycobacterium, e.g. Mycobacterium tuberculosis [2, 3]
A61K 39/05	UGR2	. . Corynebacterium; Propionibacterium [3]
A61K 39/07	UGR2	. . Bacillus [3]
A61K 39/08	UGR2	. . Clostridium, e.g. Clostridium tetani [2]
A61K 39/085	UGR2	. . Staphylococcus [3]
A61K 39/09	UGR2	. . Streptococcus [3]
A61K 39/095	UGR2	. . Neisseria [3]
A61K 39/10	UGR2	. . Brucella; Bordetella, e.g. Bordetella pertussis [2, 3]
A61K 39/102	UGR2	. . Pasteurella; Haemophilus [3]
A61K 39/104	UGR2	. . Pseudomonas [3]
A61K 39/106	UGR2	. . Vibrio; Campylobacter [3]
A61K 39/108	UGR2	. . Escherichia; Klebsiella [3]
A61K 39/112	UGR2	. . Salmonella; Shigella [3]
A61K 39/114	UGR2	. . Fusobacterium [3]
A61K 39/116	UGR2	. . Polyvalent bacterial antigens [3]
A61K 39/118	UGR1	. Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci [3]
A61K 39/12	UGR1	. Viral antigens [2]
A61K 39/125	UGR2	. . Picornaviridae, e.g. calicivirus [3]
A61K 39/13	UGR3	. . . Poliovirus [3]
A61K 39/135	UGR3	. . . Foot-and-mouth disease virus [3]
A61K 39/145	UGR2	. . Orthomyxoviridae, e.g. influenza virus [3]
A61K 39/15	UGR2	. . Reoviridae, e.g. calf diarrhea virus [3]
A61K 39/155	UGR2	. . Paramyxoviridae, e.g. parainfluenza virus [3]
A61K 39/165	UGR3	. . . Mumps or measles virus [3]
A61K 39/17	UGR3	. . . Newcastle disease virus [3]
A61K 39/175	UGR3	. . . Canine distemper virus [3]
A61K 39/187	UGR2	. . Hog cholera virus [3]
A61K 39/193	UGR2	. . Equine encephalomyelitis virus [3]
A61K 39/20	UGR2	. . Rubella virus [2]
A61K 39/205	UGR2	. . Rhabdoviridae, e.g. rabies virus [3]
A61K 39/21	UGR2	. . Retroviridae, e.g. equine infectious anemia virus [3]
A61K 39/215	UGR2	. . Coronaviridae, e.g. avian infectious bronchitis virus [3]
A61K 39/225	UGR3	. . . Porcine transmissible gastroenteritis virus [3]
A61K 39/23	UGR2	. . Parvoviridae, e.g. feline panleukopenia virus [3]
A61K 39/235	UGR2	. . Adenoviridae [3]
A61K 39/245	UGR2	. . Herpetoviridae, e.g. herpes simplex virus [3]
A61K 39/25	UGR3	. . . Varicella-zoster virus [3]
A61K 39/255	UGR3	. . . Marek's disease virus [3]
A61K 39/265	UGR3	. . . Infectious rhinotracheitis virus [3]
A61K 39/27	UGR3	. . . Equine rhinopneumonitis virus [3]
A61K 39/275	UGR2	. . Poxviridae, e.g. avipoxvirus [3]
A61K 39/285	UGR3	. . . Vaccinia virus or variola virus [3]
A61K 39/29	UGR2	. . Hepatitis virus [3]
A61K 39/295	UGR2	. . Polyvalent viral antigens (vaccinia virus or variola virus A61K 39/285); Mixtures of viral and bacterial antigens [3]
A61K 39/35	UGR1	. Allergens [3]
A61K 39/36	UGR2	. . from pollen [2, 3]
A61K 39/38	UGR1	. Antigens from snakes [2]
A61K 39/385	UGR1	. Haptens or antigens, bound to carriers [3]
A61K 39/39	UGR1	. characterised by the immunostimulating additives, e.g. chemical adjuvants [3]
A61K 39/395	UGR1	. Antibodies (agglutinins A61K 38/36); Immunoglobulins; Immune serum, e.g. antilymphocytic serum [3]
A61K 39/40	UGR2	. . bacterial [2, 3]
A61K 39/42	UGR2	. . viral [2, 3]
A61K 39/44	UGR2	. . Antibodies bound to carriers [2, 3]
A61K 41/00	HGR	Medicinal preparations obtained by treating materials with wave energy or particle radiation (A61K 31/59 takes precedence; electric discharge tubes H01J) [2]
A61K 45/00	HGR	Medicinal preparations containing active ingredients not provided for in groups A61K 31/00 to A61K 41/00 [2, 6]
A61K 45/05	GEL	(covered by A61K 45/00)
A61K 45/06	UGR1	. Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca [2]
A61K 45/08	UGR1	. Mixtures of an active ingredient and an auxiliary substance neither being chemically characterised, e.g. antihistaminicum and surface active substance [2]
A61K 47/00	HGR	Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives [2]
A61K 47/02	UGR1	. Inorganic compounds [5]
A61K 47/04	UGR2	. . Non-metals; Compounds thereof [5]
A61K 47/06	UGR1	. Organic compounds [5]
A61K 47/08	UGR2	. . containing oxygen [5]
A61K 47/10	UGR3	. . . Alcohols; Phenols; Salts thereof [5]
A61K 47/12	UGR3	. . . Carboxylic acids; Salts or anhydrides thereof [5]
A61K 47/14	UGR3	. . . Esters of carboxylic acids [5]
A61K 47/16	UGR2	. . containing nitrogen [5]
A61K 47/18	UGR3	. . . Amines; Quaternary ammonium compounds [5]
A61K 47/20	UGR2	. . containing sulfur [5]
A61K 47/22	UGR2	. . Heterocyclic compounds [5]
A61K 47/24	UGR2	. . containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen or sulfur [5]
A61K 47/26	UGR2	. . Carbohydrates [5]
A61K 47/28	UGR2	. . Steroids [5]
A61K 47/30	UGR1	. Macromolecular compounds [5]
A61K 47/32	UGR2	. . Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds [5]
A61K 47/34	UGR2	. . Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds [5]
A61K 47/36	UGR2	. . Polysaccharides; Derivatives thereof [5]
A61K 47/38	UGR3	. . . Cellulose; Derivatives thereof [5]
A61K 47/40	UGR3	. . . Cyclodextrins; Derivatives thereof [5]
A61K 47/42	UGR2	. . Proteins; Polypeptides; Degradation products thereof; Derivatives thereof [5]
A61K 47/44	UGR1	. Oils, fats or waxes according to more than one of groups A61K 47/02 to A61K 47/42 [5]
A61K 47/46	UGR1	. Ingredients of undetermined constitution or reaction products thereof [5]
A61K 47/48	UGR1	. the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates [5]
A61K 48/00	HGR	Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy [5]
A61K 49/00	HGR	Preparations for testing in vivo [3]
A61K 49/04	UGR1	. X-ray contrast preparations [3]
A61K 49/06	UGR1	. Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations [7]
A61K 49/08	UGR2	. . characterised by the carrier [7]
A61K 49/10	UGR3	. . . Organic compounds [7]
A61K 49/12	UGR4	. . . . Macromolecular compounds [7]
A61K 49/14	UGR4	. . . . Peptides, e.g. proteins [7]
A61K 49/16	UGR5	. . . . . Antibodies; Immunoglobulins; Fragments thereof [7]
A61K 49/18	UGR2	. . characterised by a special physical form, e.g. emulsions, microcapsules, liposomes [7]
A61K 49/20	UGR2	. . containing free radicals [7]
A61K 49/22	UGR1	. Echographic preparations; Ultrasound imaging preparations [7]
A61K 51/00	HGR	Preparations containing radioactive substances for use in therapy or testing in vivo [6]
A61K 51/02	UGR1	. characterised by the carrier [6]
A61K 51/04	UGR2	. . Organic compounds [6]
A61K 51/06	UGR3	. . . Macromolecular compounds [6]
A61K 51/08	UGR3	. . . Peptides, e.g. proteins [6]
A61K 51/10	UGR4	. . . . Antibodies or immunoglobulins; Fragments thereof [6]
A61K 51/12	UGR1	. characterised by a special physical form, e.g. emulsion, microcapsules, liposomes [6]
A61K 101/00	ZW	Indexing scheme associated with group A61K 51/00 , relating to the nature or the activity of the radioactive substance. The indexing codes should be unlinked. [6]
A61K 101/00	HGR	Radioactive non-metals [6]
A61K 101/02	UGR1	. Halogens [6]
A61K 103/00	HGR	Radioactive metals [6]
A61K 103/10	UGR1	. Technetium; Rhenium [6]
A61K 103/20	UGR1	. Indium [6]
A61K 103/30	UGR1	. Rare earths [6]
A61K 103/32	UGR2	. . Yttrium [6]
A61K 103/34	UGR2	. . Gadolinium [6]
A61K 103/36	UGR2	. . Ytterbium [6]
A61K 103/40	UGR1	. Actinides [6]
A61K 121/00	HGR	Preparations for use in therapy [6]
A61K 123/00	HGR	Preparations for testing in vivo [6]